Q4 Earnings Estimate for NAMS Issued By Leerink Partnrs

NewAmsterdam Pharma (NASDAQ:NAMS) – Research analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for NewAmsterdam Pharma in a report issued on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings per share of ($0.35) for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s FY2028 earnings at $0.42 EPS.

Several other brokerages have also weighed in on NAMS. Piper Sandler restated an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Needham & Company LLC reiterated a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Scotiabank raised their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Buy” and a consensus price target of $36.20.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $25.50 on Thursday. NewAmsterdam Pharma has a 52 week low of $10.50 and a 52 week high of $27.29. The stock’s fifty day moving average is $21.31 and its 200-day moving average is $18.95.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $25.02, for a total value of $213,420.60. Following the completion of the sale, the insider now owns 11,812,033 shares in the company, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 353,542 shares of company stock valued at $8,599,328. Insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. boosted its stake in NewAmsterdam Pharma by 5.1% in the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after buying an additional 628,251 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of NewAmsterdam Pharma by 51.1% in the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock worth $25,607,000 after purchasing an additional 520,772 shares during the last quarter. Millennium Management LLC boosted its holdings in NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after acquiring an additional 217,902 shares during the last quarter. Jennison Associates LLC raised its stake in NewAmsterdam Pharma by 8.9% during the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock worth $16,937,000 after buying an additional 83,115 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its stake in shares of NewAmsterdam Pharma by 30.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock valued at $16,698,000 after purchasing an additional 202,250 shares during the period. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.